<DOC>
	<DOCNO>NCT00199407</DOCNO>
	<brief_summary>To establish efficacy 20 mg/day dose istradefylline reduce percentage OFF time patient advance Parkinson 's disease ( PD ) treat levodopa .</brief_summary>
	<brief_title>A Study Istradefylline ( KW-6002 ) Treatment Parkinson 's Disease Patients Taking Levodopa</brief_title>
	<detailed_description>To establish efficacy 20 mg/d dose istradefylline reduce percentage OFF time patient advance Parkinson 's disease ( PD ) treat levodopa . Patients meet entry criterion randomize 1 1 ratio either istradefylline matching placebo . Patients treat 12 week interim visit end treatment visit ass efficacy safety istradefylline compare placebo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . UK Parkinson 's Disease Society ( UKPDS ) brain bank criterion ( Step 1 2 ) PD . 2 . PD stag 24 OFF state Modified Hoehn Yahr Scale . 3 . On levodopa/carbidopa least one year , stable dose past 4 week . 4 . Currently take least three dos levodopa/carbidopa per day . 5 . Predictable end dose wear . 6 . Able satisfactorily complete Hauser version Parkinson 's diary . 7 . Have average 180 minute OFF time two 24 hour diary . 8 . Be least 30 year age . 1 . Neurosurgical treatment PD . 2 . History psychosis . 3 . Diagnosis atypical parkinsonism , secondary parkinsonism variant Parkinson 's plus syndrome . 4 . Diagnosis cancer within 5 year . 5 . Minimental status examination score 25 less . 6 . History seizures neurologic malignant_syndrome . 7 . Clinical depression .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end dose wear</keyword>
	<keyword>OFF time</keyword>
</DOC>